Innoviva Current Ratio 2006-2020 | INVA

Innoviva current ratio from 2006 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Innoviva Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-06-30 $0.50B $0.01B 92.39
2020-03-31 $0.47B $0.00B 166.87
2019-12-31 $0.43B $0.01B 80.29
2019-09-30 $0.37B $0.00B 110.18
2019-06-30 $0.32B $0.01B 42.50
2019-03-31 $0.25B $0.00B 66.02
2018-12-31 $0.20B $0.01B 34.92
2018-09-30 $0.12B $0.00B 28.18
2018-06-30 $0.18B $0.01B 26.36
2018-03-31 $0.11B $0.00B 27.85
2017-12-31 $0.20B $0.04B 5.77
2017-09-30 $0.22B $0.03B 6.71
2017-06-30 $0.20B $0.03B 7.31
2017-03-31 $0.21B $0.02B 10.47
2016-12-31 $0.20B $0.02B 9.88
2016-09-30 $0.19B $0.02B 12.47
2016-06-30 $0.19B $0.02B 13.02
2016-03-31 $0.20B $0.01B 18.52
2015-12-31 $0.21B $0.01B 15.89
2015-09-30 $0.22B $0.01B 19.84
2015-06-30 $0.24B $0.01B 19.97
2015-03-31 $0.26B $0.01B 23.90
2014-12-31 $0.25B $0.01B 18.33
2014-09-30 $0.27B $0.04B 7.58
2014-06-30 $0.35B $0.05B 7.06
2014-03-31 $0.39B $0.04B 8.82
2013-12-31 $0.48B $0.08B 5.73
2013-09-30 $0.52B $0.04B 13.51
2013-06-30 $0.46B $0.04B 11.83
2013-03-31 $0.48B $0.03B 16.11
2012-12-31 $0.26B $0.03B 8.71
2012-09-30 $0.28B $0.03B 10.43
2012-06-30 $0.30B $0.03B 11.77
2012-03-31 $0.20B $0.03B 7.99
2011-12-31 $0.25B $0.05B 5.38
2011-09-30 $0.27B $0.04B 6.76
2011-06-30 $0.29B $0.04B 8.20
2011-03-31 $0.30B $0.03B 8.99
2010-12-31 $0.32B $0.04B 7.90
2010-09-30 $0.20B $0.04B 5.43
2010-06-30 $0.22B $0.04B 6.01
2010-03-31 $0.23B $0.04B 6.53
2009-12-31 $0.16B $0.04B 4.16
2009-09-30 $0.16B $0.04B 4.14
2009-06-30 $0.18B $0.04B 4.57
2009-03-31 $0.19B $0.04B 5.08
2008-12-31 $0.21B $0.04B 4.78
2008-09-30 $0.23B $0.04B 5.21
2008-06-30 $0.25B $0.05B 5.03
2008-03-31 $0.27B $0.05B 5.40
2007-12-31 $0.13B $0.06B 2.42
2007-09-30 $0.14B $0.06B 2.53
2007-06-30 $0.16B $0.06B 2.62
2007-03-31 $0.19B $0.06B 3.03
2006-12-31 $0.21B $0.06B 3.48
2006-09-30 $0.23B $0.06B 4.15
2006-06-30 $0.25B $0.05B 4.58
2006-03-31 $0.27B $0.05B 5.03
2005-12-31 $0.17B $0.05B 3.46
2005-09-30 $0.18B $0.04B 4.38
2005-06-30 $0.21B $0.04B 5.56
2005-03-31 $0.24B $0.04B 6.62
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.404B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.658B 18.57
Roche Holding AG (RHHBY) Switzerland $295.923B 0.00
Pfizer (PFE) United States $212.106B 13.25
Merck (MRK) United States $211.293B 15.08
Novartis AG (NVS) Switzerland $195.386B 15.19
AbbVie (ABBV) United States $167.094B 10.18
Novo Nordisk (NVO) Denmark $157.442B 25.62
AstraZeneca (AZN) United Kingdom $146.440B 28.47
Eli Lilly (LLY) United States $143.911B 21.97
Sanofi (SNY) $128.638B 15.29
GlaxoSmithKline (GSK) United Kingdom $103.326B 13.55
Bayer (BAYRY) Germany $63.264B 9.12
H Lundbeck (HLUYY) Denmark $7.269B 12.63